NASDAQ:GRTS
Delisted

Gritstone Oncology Stock News

etoro logo Buy GRTS
*Your capital is at risk
$0.0322
+0 (+0%)
At Close: Nov 05, 2024
Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multip
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 30) Achieve Life Sciences Inc (NASDAQ: ACHV) Annexon Inc (NASDAQ: ANNX) (IPOed July 24) Atossa Therapeutics...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Adamis Pharmaceuticals Corp (NASDAQ: ADMP) Annexon...
Despite some good news out of specific companies, this was not a great week for cannabis stocks overall. Over the five trading days of the week: ETFMG Alternative Harvest ETF (...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) Bio-Rad Laboratories,...
A look at the shareholders of Gritstone Oncology, Inc. (NASDAQ:GRTS) can tell us which group is most powerful...
H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Gritstone Oncology (GRTS – Research Report) on July 14
Phase 1 included 5 patient cases to evaluate clinical benefit. 3 of the 5 patients exhibited clinical benefit with 1 MSS-CRC patient showing clear therapy efficacy.
Gritstone Oncology (NASDAQ:GRTS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. The bro
State Street Corp grew its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 8.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The
Gritstone Oncology (NASDAQ:GRTS) had its price objective lowered by analysts at BTIG Research from $31.00 to $17.00 in a research report issued to clients and investors on Tuesday, MarketBeat.com repo
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Altimmune Inc (NASDAQ: ALT...
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE